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Abstract: Background
Breast cancer brain metastases (BCBM) are an increasing clinical problem. Recent
studies have shown a distinct genomic landscape in breast cancer brain metastases
including mutations absent in the primary tumour. The aim of this study was to produce
a systematic review of the genomic landscape of BCBM.
 
Patients and methods
We performed a systematic search of Scopus covering dates from inception to 30th
April 2020. Mutations data was extracted for mutations, receptor status
[immunohistochemistry (IHC) and PAM50] and copy number alterations (CNAs) from
the published manuscript and supplementary materials. STRING pathway analysis was
performed on the 22 most commonly mutated genes and the drugs-genes interactions
database (DGIdb) was used to access their actionability.
 
Results
We reviewed 13 studies comprising 164 patients where BCBMs had been sequenced.
A list of 268 mutated genes was identified which occurred in at least two of the
sequenced BCBMs. Of these, 22 genes were mutated in five or more patients and the
most commonly mutated were the TP53 and PIK3CA genes. Pathway enrichment
analysis showed that the 22 genes are involved in breast cancer-related signalling
pathways, in regulation of gene transcription, cell cycle and DNA repair. Actionability
analysis revealed that 68% of these genes are actionable drug targets.  In addition,
IHC and PAM50 data showed a receptor discordancy between primary breast cancers
and paired brain metastases.
 
Conclusions
This systematic review provides a conclusive overview of the commonest mutated
genes identified in BCBM and their clinical relevance. In addition, the IHC and PAM50
switching between primary BC and BM highlights further the importance of acquiring
and assessing BCBMs.
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Breast cancer brain metastases (BCBM) are an increasing clinical problem. Recent studies have 
shown a distinct genomic landscape in breast cancer brain metastases including mutations 
absent in the primary tumour. The aim of this study was to produce a systematic review of the 
genomic landscape of BCBM. 
 
Patients and methods 
We performed a systematic search of Scopus covering dates from inception to 30th April 2020. 
Mutations data was extracted for mutations, receptor status [immunohistochemistry (IHC) and 
PAM50] and copy number alterations (CNAs) from the published manuscript and 
supplementary materials. STRING pathway analysis was performed on the 22 most commonly 




We reviewed 13 studies comprising 164 patients where BCBMs had been sequenced. A list of 
268 mutated genes was identified which occurred in at least two of the sequenced BCBMs. Of 
these, 22 genes were mutated in five or more patients and the most commonly mutated were 
the TP53 and PIK3CA genes. Pathway enrichment analysis showed that the 22 genes are 
involved in breast cancer-related signalling pathways, in regulation of gene transcription, cell 
cycle and DNA repair. Actionability analysis revealed that 68% of these genes are actionable 
drug targets.  In addition, IHC and PAM50 data showed a receptor discordancy between 




This systematic review provides a conclusive overview of the commonest mutated genes 
identified in BCBM and their clinical relevance. In addition, the IHC and PAM50 switching 
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Research in Context 
Evidence before this study:  
Searches were performed of PubMed, Embase, and Scopus databases for articles published 
between the inception of the database and 30th April 2020. Search terms were developed using 
a combination of MeSH keywords and wildcards. PubMed was searched for breast AND brain 
AND metast* AND sequenc*. Inclusion criteria were studies of four or more patients, 
published in English where genomic sequencing of brain metastases had been performed with 
data presented for single nucleotide variant mutations with at least one specific point mutation 
identified and presented in the article or supplementary information. We found that studies of 
BCBM are general much smaller than comparable sequencing studies for extra cranial disease. 
These studies have often not compared the brain metastasis to the paired primary cancer. These 
studies that have provide evidence that breast cancer brain metastasis can be genomically 
distinct from the primaries they arise from. To our knowledge, no publications so far have 
synthesised the genomic data contained within these studies of breast cancer brain metastasis. 
 
Added value of this study:  
Our study provides a comprehensive and detailed overview of sequencing studies related to 
brain metastasis secondary to breast cancer. By bringing all these brain metastasis studies 
together we provide a detailed overview and summary of these important data.  A direct 
comparison of the genomic aberrations contained within breast cancer brain metastasis to those 
reported within large sequencing studies of extra cranial disease demonstrates that while there 
is some overlap in the genomic aberrations there is a clear divergence between cranial and 
extra-cranial disease.  Undertaking a STRING pathway analysis of these genomic aberrations 
within breast cancer brain metastasis demonstrates enrichment for breast cancer-related 
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pathways as well as those involved in the regulation of gene transcription, cell cycle and DNA 
repair. While an assessment of actionality reveals the majority of these mutations are 
potentially actionable with clear therapeutic relevance. The data also reveals that PAM50 
switching occurs in majority of cases providing further evidence regarding the divergence 
between the primary and brain metastasis.  
 
Implications of all the available evidence:  
These findings emphasise the importance of accessing and sequencing brain metastasis and for 
considering brain metastasis as being genomically distinct from extra cranial disease. The 
number of mutations which are actionable suggest there are a number of possible therapeutic 





Breast cancer (BC) is the second most common solid malignancy to involve the central nervous 
system (CNS).1 BC is a heterogeneous disease which is classified into clinically relevant 
groups by immunohistochemistry (IHC) and in situ hybridisation (ISH)  for oestrogen receptor 
(ER) and progesterone receptor (PR), human epidermal growth factor receptor (HER2) status 
or lack of receptor expression.2,3 Alternatively BC can be classified by the PAM50 gene 
expression profile into luminal A, luminal B , HER2 enriched, basal and normal breast-like 
subtypes.2,4 With regard to metastatic behaviour these subtypes display differing predictions 
for distant organs, including brain metastasis, as identified by Zhang et al.5 In TNBC, brain 
metastasis occurs either as the first site of distant spread (26% of patients) or after 
dissemination to the lungs, whereas in luminal subtype, distant spread to the bones and lungs 
is more frequent with brain metastasis uncommon.6 Patients with the luminal subtype of breast 
cancer tend to have a better prognosis compared to HER2-positive and TNBC. Breast cancer 
brain metastasis (BCBM) is a particular feature of HER2-positive and triple negative BC, with 
a 2 to 5-fold increased risk of developing BM compared to luminal cancers.7,8 
Nearly all breast-cancer deaths are related to metastasis rather than the primary cancer and 
recent clinical data has shown that BCBM is an increasing clinical problem in metastatic breast 
cancer (MBC).9,10 This is likely to be a reflection of women with MBC living longer with 
improvements in systemic therapy, particularly in the HER2 positive subgroup and increased 
cross-sectional imaging of the central nervous system.10,11 A particular clinical challenge is the 
development of new onset or progressive brain metastases in the setting of extracranial disease 
that is adequately controlled. BCBM is a cause of significant morbidity and mortality and 
despite this, patients with BCBM have been disadvantaged by a relative lack of clinical 
research in this area, in fact such patients are often explicitly excluded from clinical trials.12 
Progress is further hampered by the lack of annotated collection of biological material to 
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underpin translational research in this area.13 The current standard of care for newly diagnosed 
BM includes surgery, stereotactic radiosurgery (SRS), and/or whole brain radiotherapy 
(WBRT).6 Systemic therapy is in general the standard of care if there is progressive disease 
following local therapy.14 Aside from tucatinib for HER2 positive breast cancer there is a  lack 
of effective systemic treatments making this an area of unmet clinical need and an important 
avenue of research with the possibility to help a currently underserved sub-population of MBC 
patients.  
The advent of the age of genomic medicine has enabled the characterisation of tumours for 
diagnosis, progression and the choice of therapeutic options. In addition, it has enabled a deeper 
understanding of the evolutionary process of breast cancer and the development of metastasis 
by comparing primaries with secondary cancers.15 Two recent studies have sequenced a total 
of 1242 BC metastases , all extracranial,16,17 however sequencing studies of BCBM have been 
very limited in the number of patients as it will be further appraised in this review.18-30 
Obtaining samples for genomic work in patients with BCBM is difficult given the inherent 
risks and complexity of neurosurgery, as well as the fact that the procedure may not be always 
appropriate due to the occurrence of multiple lesions. The increasing use of SRS has reduced 
the need for surgical resection but also, the availability of tissue, whereas longitudinal tissue 
sampling is clinically feasible.13  
The importance of treating the disease in the brain separately from any prior extracranial 
disease was demonstrated in a study of 86 paired primary and BM of which 21 were primary 
BC and their matched BM.18 This study demonstrated that while the primary and BM shared a 
common ancestor, both the primary tumour and the metastasis continued to evolve separately, 
reflected by the presence of distinct mutations so called ‘private mutations’ and each sample 
continued to develop minor cancer-cell populations. In addition, where the regional lymph 
nodes, or extracranial metastases were available these were shown not to be reliable surrogates 
 8 
for the oncogenic alterations found in the BM. Inter-lesional and intra-lesional sampling of the 
BM demonstrated significant genetic homogeneity; with BM samples having mutations that 
were not detected in the clinically sampled primary tumour, indicating that the subclones 
sampled in these lesions were more closely related to one another than to those detected in the 
primary tumour. In approximately half of cases, clinically informative alterations which were 
found in the BM were not detected in the matched primary tumour. These data emphasise the 
need to analyse BMs as a distinct entity rather than relying solely on information from either 
the primary or the extracranial systemic disease, as well as offering opportunities for innovative 




Search strategy and selection criteria 
This study was designed as a systematic review of the published literature. Searches were made 
of PubMed, Embase, and Scopus databases for articles published between the inception of the 
database and 30th April 2020. Search terms were developed using a combination of MeSH 
keywords and wildcards. PubMed was searched for breast AND brain AND metast* AND 
sequenc*. Inclusion criteria were studies of four or more patients, published in English where 
genomic sequencing of brain metastases had been performed with data presented for single 
nucleotide variant mutations (SNV) with at least two specific point mutations identified and 
presented in the article or supplementary information. Data searches and extraction were 
performed by AM and AG in consultation with CP. There were no disagreements over studies 
to be included in the review.   
 
Data extraction 
This study was performed as a systematic review of the literature in accordance with the 
PRISMA statement.31 The flow of information through the different phases of this systematic 
review are illustrated in Figure 1. As the data used was the published data in the manuscript 
and the supplementary information and there was observed variation in the genes reported in 
each study a full meta-analysis was not feasible. Data were extracted from the published 
manuscript and any supplementary files available from the journal website where it was 
presented as text, figures and tables. Data were compiled in Microsoft Excel with further 
analysis and preparation of figures in R3·6.32 There was no duplication of data between studies. 
Study information was extracted for the following characteristic; Number of patients and 
clinicopathological characteristics including immunohistochemistry (IHC) and PAM50 status 
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where available, whether sequencing was of matched pairs of material or BM alone, 
sequencing platform, source of material, and sample preservation method. Mutated genes were 
analysed per-study and per-patient basis. From the study data, a list was generated of the point 
mutations in the most commonly reported genes. In the cases where genes were reported to be 
mutated but the point mutations were not presented, the data was excluded. Data on copy 
number alterations (CNAs) was also included in this review from the studies presenting the 
highest number of cases. 
 
Pathway and actionability analysis 
Functional pathway enrichment analysis (KEGG and REACTOME) of the 16 commonly 
mutated genes was performed using the STRING (Functional protein association networks) 
database v11 (string-db.org). Clustering was also performed using the K-means algorithm that 
aims to group a given dataset into clusters.  The genes in the same cluster are considered more 
similar than other ones in different clusters.  
The actionability of the 16 commonly mutated genes was assessed by the Drug-Gene 
interactions database (DGIdb) v3.1 (http://www.dgidb.org/).33 DGIdb includes 39 potentially 
druggable categories with at least 35 interaction types as defined by several source datasets; 
DrugBank, Therapeutic Target Database (DTT), PharmGKB, OncoKB, Cancer Genome 
Interpreter (CGI), Memorial Sloan Kettering IMPACT (MskIMPACT), Clinical 
Interpretetions of Variants in Cancer (CIViC), FDA Pharmacogenomic biomarkers, Database 
of Curated Mutations (DoCM), The Jackson Laboratory Clinical Knowledgebase (CKB), NCI 




Of the 430 articles returned by the search, 13 were included in the final review after the 
application of our inclusion criteria. These 13 studies comprised 167 patients of which 164 
were sequenced, all female, with the patients’ characteristics summarised in Table 1 whereas 
additional information regarding age and median times for diagnosis of BM and survival are 
presented in supplementary table 1. Sequencing of matched pairs of primary breast tumour and 
brain metastases was conducted in 129 of these patients. Of the 13 studies, 4 (30·8%) were of 
BCBMs only, 5 (38·5%) studies reported BCBM as part of sequencing various MBC sites and 
four (30·8%) reported BCBM as part of sequencing from different primaries. Eight studies 
(61·5%) used material from resection with 3 (23·1%) from post-mortem, 1 from both (7·7%) 
and 1 (7·7%) did not report where the material derived from (Table 2). Three studies (23·1%) 
used snap-frozen samples, 6 (46·2%) used formalin-fixed paraffin-embedded tissue and 4 
(30·1%) used both preservation methods. This information of the different sequencing 
platforms, the clinical material and their receptor status by IHC or PAM50 including the source 
of the extracted data is summarised in Table 2.  
 
BCBM Mutations and pathway analysis 
Overall, 268 genes were reported as mutated in two or more of the 164 BCBMs (Supplementary 
file 1: Mutated genes). Of these, 22 genes (8·2%) (Supplementary file 1: Mutated genes, 
highlighted in blue) were reported to be mutated in five or more brain metastases and they were 
selected for further review. These genes in order of decreasing frequency were (n= number of 
BCBMs with mutations in brackets and percentages); TP53 (n=85, 51·8%), PIK3CA (n=36, 
22·0%), KTMT2C (n=10, 6·1%), RB1 (n=8, 4·9%), ZFHX3  (n=8, 4·9%), BRCA2 (n=7, 
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4·3%), ERBB2 (n=7, 4·3%), KMT2D (n=7, 4·3%), MLH1 (n=7, 4·3%), PTEN (n=7, 4·3%), 
ATR (n=6, 3·7%), BRCA1 (n=6, 3·7%), CDH1 (n=6, 3·7%), COL6A3 (n=6, 3·7%), FAT1 
(n=6, 3·7%), FLT3 (n=6, 3·7%), IGFN1 (n=6, 3·7%), ARID1A (n=5, 3·0%), ATM (n=5, 
3·0%), CHEK2 (n=5, 3·0%), MAP3K1 (n=5, 3·0%), MET (n=5, 3·0%) (Figure 2A). We 
compared our list of the 22 most frequently mutated genes to the data of two large-scale 
extracranial sequencing studies of BC metastasis (Supplementary table 2).16,17  Seven out of 
the 22 (31·8%) genes reported in five and more patients in our aggregation were also present 
in the top 21 reported mutated genes in the study by Angus et al.17 with five found in the top 
10 (50·0%) reported by Bertucci et al.16 The remaining 13 (61·9%) genes (ATM, ATR, 
BRCA1, BRCA2, CHEK2, COL6A3, FAT1, FLT3, IGFN1, KMT2D, MET, MLH1, ZFHX3) 
were not present anywhere on the list of 21 cancer-driving genes presented in either of the 
extracranial sequencing studies.16,17 It is of note that the 2 most commonly reported genes in 
both the extracranial studies and in this review were TP53 and PIK3CA. 
The 22 frequently mutated genes were further subjected to functional pathways analysis. The 
functional protein-protein interaction network as generated by STRING is illustrated in Figure 
2B. KEGG pathway enrichment analysis indicated that the 22 highly mutated genes are present 
in pathways in cancer, breast cancer, drug resistance, cellular senescence and PI3K-AKT, 
TP53, MAPK, FOXO signalling pathways among other cancer related pathways with false 
discovery rate (FDR) less than 0.001. The breast cancer related pathways including glioma are 
illustrated in Figure 2C. REACTOME functional enrichment showed that mutated genes are 
involved in the regulation of gene transcription, cell cycle and DNA repair whereas k-means 
clustering (Figure 2D) grouped the genes into 3 clusters mainly involved in cell cycle, growth 
arrest, DNA repair and signal transduction/transcription. (red), signalling pathways (yellow) 
and transcriptional activation and cell migration (green). Two genes, the COL6A3 (cyan) and 
IGFN1 (blue) remained individually. COL6A3 as a cell binding protein is involved in 
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extracellular matrix and adhesion but the functional role of IGFN1 (Immunoglobulin-like and 
fibronectin type III domain containing 1) is not established. All the pathway analysis data is 
available in Supplementary file 1: KEGG, REACTOME and kmeans clustering. 
 
Actionability of mutated genes 
The actionability of the 22 commonly mutated genes was investigated by the DGIdb 
(http://www.dgidb.org/).33 Eighteen of the 22 genes (81.8%) were present on the generated list 
of drugs and genes interactions (Supplementary file 1: DGIdb) and 15 (68.2% ) of these are or 
can potentially be useful drug targets. Eight genes (36.4%), PIK3CA, MET, ERBB2, FLT3, 
ATR, ATM, TP53 and MAP3K1 were targetable. TP53 cannot be directly targeted but re-
activated by several strategies that include targeting of molecules that modulate its 
posttranslational modifications, localization, synthesis and its degradation.34,35 Seven genes 
(31.8%), BRAC1, BRAC2, RB1, PTEN, CDH1, CHEK2 and MLH1 were actionable providing 
biallelic inactivation was present. MLH1 can also act as a biomarker for selecting 
immunotherapy efficacy.36 Three of the genes (13.6%) ARID1A, KMT2D and COL6A3 were 
present on our DGIdb list but the information was poor to justify any clinical relevance.33 No 
interactions were identified for four genes (18.2%) FAT1, ZFHX3, KMT2C and IGFN1.  
 
Copy Number Alterations 
Whilst copy number alterations (CNA) were not a primary outcome of this review we have 
presented the summarised data below. Five of 13 studies (38·5%)18,21,26,27,29 comprising 67 
patients in total (40·1%) reported CNA in 2 or more patients in a total of 50 genes 
(Supplementary file 1: CNAs). Of these, 19 genes (22·6%) had CNA in five or more BCBM 
patients presented here as n= number of patients with reported CNA and percentage of patients 
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with reported CNA from these five studies, ERBB2 (n= 27, 40·3%), MYC (n=18, 26·9%), 
CCND1 n=10, 14·9%), RB1 (n=8, 11·9%), ADAM28 n=7, 10·4%), CDK12 (n=7, 10·4%), 
NRG1 (n=7, 10·4%), AURKA (n=6, 9·0%), DPYSL2 (n=6, 9·0%), FGF3 (n=6, 9·0%), MDM4 
(n=6, 9·0%), ROBO3 (n=6, 9·0%), TP53 (n=5, 7·5%), BRCA2 (n=5, 7·5%), EGFR (n=5, 
7·5%), FGF4 (n=5, 7·5%), FGFR1 (n=5, 7·5%), SLIT1 (n=5, 7·5%), UNC5D (n=5, 7·5%).  
 
Immunohistochemistry 
Immunohistochemistry (IHC) status was reported in all studies, in a total of 136 primary and 
121 metastatic samples (Supplementary file 2: Primary IHC, Metastasis IHC). The studies 
reporting IHC status of the primary BC and of the BM are presented in Table 3A and 3B 
respectively. It was possible to determine the status of all 3 receptors in 77 (56·6%) primary 
and 66 (55%) metastatic cases. In the primary BC, 34 of 136 samples (25·0%) were reported 
as TN, 47 (34·6%) as ER+/HER2± and 59 (43·4%) as HER2+/ER±. In the metastatic samples, 
34 (28%) were reported as TN, 44 (26·3%) as ER+/HER2± and 60 (35·9%) as HER2+/ER±. 
Of the ER- cases where PgR status was available, 4 out of 50 (8%) primary BCs and 3 out of 
the 37 (8%) BMs were PgR-positive. 
Paired samples for 67 patients were available from the studies by Da Silva, Lee, Saunus, 
Diossy, and Tyran19-21,28,29 (Supplementary file 2: Pair cases IHC). After the removal of 
incomplete data and patients with multiple primary or secondary samples, data was available 
for 51 patients with an overall discordancy of 22% between primary and metastasis. ER status 
was discordant in 4 cases (8%), PgR in 4 cases (8%), and HER2 was discordant in 5 cases 
(10%). As can be seen in figure 4A there is a trend towards TNBC and HER2-positive subtypes 
from primary to metastasis (39% to 45%) and (22 to 24%) respectively and away from the 




PAM50 status was reported in 3 of the 12 studies, 2 reported both primary and metastatic status 
and 1 study reported the PAM50 status of the primary tumour alone as summarised in Table 4. 
These two studies were Lee et al.20 and Siegel et al.25 comprising 21 patients in total (13%). Of 
these, 20 patients had complete data available with 1 patient with unknown status in the 
metastasis. The summary of those with complete data showed discordancy in 11 of 20 (55%) 
of cases between primary and metastasis. Figure 3B illustrates the switching of PAM50 profiles 
between primary and metastases. There was significant discordancy between PAM50 subtypes 
in primary and metastatic tissue with a trend away from basal-like (45% to 30% primary to 
secondary) in the primary tissue to normal-like in the metastatic tissue (10% to 30%). Two 





In this systematic review we have compiled the mutation data and CNAs presented in twelve 
BCBM sequencing studies and generated a comprehensive overview of the genomic landscape 
of BCBM. We also extracted the data for IHC and PAM50 status from these studies and 
elaborated further on the discrepancies between primary BC and their matched brain 
metastases. 
Of the twelve BCBM studies included in this review, nine utilised a variety of Illumina NGS 
platforms, two utilising the ThermoFisher Ion-PGM platform whereas Da Silva et al.19 used 
the OncoCartaTM v1.0 kit on the MassARRAY system (Agena Bioscience, San Diego, USA), 
a mass spectrometry based on matrix assisted laser desorption/ionisation-time of flight 
(MALDI-TOF). Despite having a different methodology to the others, the study was included 
due to the large number of matched BC and BM patients (12 matched cases). In addition, the 
main difference of the MassARRAY in comparison to NGS on the identification of mutations 
is the use of predefined mutations across different oncogenes; it cannot therefore detect 
unknown mutations and CNAs.37 
Comparison between these comprehensive BCBM dataset and those from two datasets of 
sequenced extracranial metastases identified several differences with genes mutated in BCBM 
but not in extracranial metastases and vice versa.16,17 Moreover, the coefficients of correlation 
between this review and the extracranial studies highlighted further the divergences between 
BCBM and other metastatic sites secondary to BC, endorsing the investigation of BCBM as 
distinct entities to extracranial metastases. The most frequently mutated genes in our current 
study, as in Bertucci16, and Angus17 were TP53 followed by PIK3CA. Similarly, in a recent 
study by our group utilising the UltraSEEK™ breast cancer panel (Agena Bioscience, San 
Diego, USA) on the MassARRAY system, the common mutated genes within a cohort of 32 
paired BCs and BCBMs were TP53, PIK3CA, AKT1 and ESR1.38 The presence of ESR1 and 
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AKT1 mutations within our cohort is a reflexion of the large number of ER positive cases in 
comparison to ER negative whereas in this systematic review only the 30% of the cases were 
ER-positive.  
As 85 (51·8%) and 36 (22·0%) patients had reported mutations in TP53 and PIK3CA 
respectively, these 2 genes represent the most obvious targets for intervention. Most recently, 
PI3Kα-specific inhibitor alpelisib, has shown activity in PIK3CA mutant breast cancer.39  
While the brain penetrant inhibitor paxalisib (GDC-0084) has demonstrated activity in pre-
clinical models of breast cancer brain metastasis40 as well as preliminary clinical activity in 
glioblastoma.41  In addition, a number of ongoing clinical trials are using p53-reactivating 
compounds in combination with different chemotherapeutic drugs but there are still certain 
limitations such as the development of systemic toxicities to overcome.33-35  
While TP53 and PIK3CA are commonly mutated in brain and extracranial metastases, our 
aggregated BCBM data also shows that only 31·8% of the frequently mutated genes overlapped 
with those frequently mutated in the extracranial metastases.16,17 This supports the previous 
observations showing divergence between extracranial and CNS metastases. The genes that 
divert from the extracranial mutated genes are mainly involved in cell cycle and DNA repair 
pathways and MET signalling. Of these genes, MLH1, ATR, CHEK2, BRCA1, BRCA2, FLT3 
and MET have been identified as druggable targets by our DGIdb analysis highlighting their 
importance in BCBM and the need for further investigation.  
In addition, four of the genes identified with CNAs (TP53, ERBB2, RB1, BRAC2) in 5 or 
more BCBM patients were also frequently mutated in this study, highlighting further the 
significance of genomic alterations in these genes and their relevant pathways. 
A pathway analysis was conducted on the 22 commonly mutated genes identified in this 
systematic review and we observed that they are mainly involved in the regulation of gene 
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transcription, cell cycle, DNA repair and signalling. As expected, since most of them are well 
known oncogenes or tumour suppressors, they were identified in KEGG pathways in cancer, 
breast cancer, drug resistance, senescence and PI3K-AKT, TP53, MAPK signalling. This data 
highlights further the importance of these mutated genes and the need for targeted therapies as 
alterations in cell cycle, DNA repair, gene transcription and signalling comprise some of the 
hallmarks of cancer.42 
A comprehensive study of receptor conversion in breast cancer reported that ER discordance 
between primary and CNS metastases was 20.8% [95% confidence interval (CI) 15-28%] 
whereas the HER2 CNS discordance was 12.5% (95% CI: 7.8-13.6%).43 In another study 
within our group, analysing 40 cases of primary BC and their matched BM, we observed that 
the distribution of the subtypes changed in the BM setting with the majority of ER-positive 
primaries losing their ER status (47.6% ER-positive) whereas no change was observed between 
the HER2-positive and the TNBCs.44 In this systematic review, we identified an 8% 
discordancy in ER status and a 10% discordancy in HER2 status between primary BC and BM. 
We also observed a total discordancy of 55% in the PAM50 status between primary BC and 
BM. This variation justifies further the need to assess the receptor status of the metastases. The 
heterogeneous findings between the studies can be due to the primary tumour characteristics 
and the time interval between primary BC and brain metastasis. Indeed, ER positive BCs have 
a better prognosis and a slow rate of relapse and distant metastasis whereas HER2 positive and 
triple negative BC can relapse quicker and sometimes, brain is their first site of metastasis. 
Moreover, receptor conversion is the result of both clonal selection and selective pressure of 
therapy.18,26,43 Although clonal selection can be observed due to the different mutations 
between primary BCs and BMs,18,26 we did not assess the therapeutic regimes as it was not the 
primary scope of this review. Nevertheless, this data confirms the heterogeneity of BC and 
 19 
supports further the importance of accessing the receptor status and/or intrinsic subtype of 
BCBM.   
The challenges however to obtain BM samples for sequencing or receptor screening are 
reflected in the total number of patients included in the studies analysed in this systematic 
review. Some of these challenges include the inherent risks of neurosurgery, as samples can 
only be taken when surgical resection is clinically indicated, making longitudinal studies of the 
changes in the BM genome unethical. In addition, for multiple metastases resection is often not 
indicated. Instead, the usage of SRS for the treatment of BM has been increasing. The benefits 
of this method to patients are obvious, however it makes it impossible to collect surgical 
samples and therefore, samples can only be collected post-mortem.  
There have been several investigations into the use of circulating cell-free DNA (cfDNA) in 
the CSF as a ‘liquid biopsy’ of BCBMs. Despite promising initial results, these studies have 
not been conclusive.18,22 Should cfDNA prove a reliable surrogate for biopsy of BMs it is likely 
that in the future patients will be able to have tailored treatments based on the results of 
sequencing cfDNA from CSF rather than relying on the genomics of the primary lesion.  
It is important to note that the lack of a report of a mutation in this review is not confirmation 
of absence of the mutation. For this reason, it was not appropriate to calculate mutation 
prevalence over the entire study population as in a meta-analysis. In addition, it was beyond 
the scope of this review to attempt to discriminate between pathogenic variants, passenger 
variants, and variants of unknown significance.  
 
Conclusion 
This is the first systematic review into the genomic landscape of BCBM that combined multiple 
smaller studies to produce more convincing and powerful findings. Several of the genes found 
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to be mutated present potential therapeutic targets whereas the receptor status switching 
between primary BC and BCBM suggests that the divergence of the genome of BCBM from 
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Figure 1. Flow of information through the different phases of the systematic review. The 
diagram illustrates the number of records identified throughout the literature, the number of 
included and excluded records, and the reasons for exclusions according to the PRISMA 
statement. 
 
Figure 2. Frequently mutated genes and pathway enrichment analysis by STRING. 
(A) The 22 genes mutated in five or more brain metastases presented in order of decreasing 
frequency. (B) Protein–protein interaction network of the 22 mutated genes as visualized by 
STRING. The colour saturation of the edges represents the confidence score of a functional 
association; higher the confidence score, the darker the grey lines. (C) KEGG pathway 
enrichment analysis plot of the main breast cancer-related pathways with FDR<0.001. The 
orange line represents the log10 ratio of observed/background gene count. (D) k-means 
clustering grouped the genes into 3 main clusters: cell cycle, growth arrest, DNA repair and 
signal transduction/transcription. (red), signalling pathways (yellow) and transcriptional 
activation and cell migration (green). The COL6A3 (cyan) and IGFN1 (blue) did not clustered 
with any other genes. Inter-cluster edges are represented by the dash-lines.  
 
Figure 3. The receptor switch between primaries breast cancer and brain metastases.  
(A) Represents the receptor switch between primaries BC and BCBM as recorded by 
immunohistochemistry (IHC) whereas in (B) is the PAM50 receptor switch between primary 





Table 1. Summary of patient characteristics in the 12 included studies. The table 
summarises the total number of patients of each study, the number of matched primary breast 
cancers and their brain metastases (BM), age, time between diagnosis and BM and survival 
time. All are median values including (range)/years. Please refer to supplementary table 1 for 
per-paper definitions of characteristics * Richichi et al.24 sequenced 10 out of 12 patients 
*Siegel et al.25 sequenced 5 out of 6 patients taking the total number of breast cancer brain 
metastasis patient with sequencing data to 164. 
 
 Total Number of breast 












 Total Matched primary 
/ metastatic pairs 
 
Da Silva (2010) 19 12 12 48·5  3·5 NR 
Lee (2015) 20 45 15 44·6 (22·4-64·1) 2·5 (0-17·7) 5.1 (0·8-20·0) 
Saunus (2015) 21 11 11 51·0 (35·8-74·9) 2·3 (0·7-25·9) 0·5 (0·3-0·9) 
Brastianos (2015) 18 21 21 46.2  3·7 NR 
De Mattos-Arruda 
(2015) 22 
4 4 36·5 (33·0-56·0) 7·9 NR 
Muller (2016) 23 4 0 47·5 (64·0-75·0) NR NR 
Richichi (2017) 24 12* 12 46·0 (32·0-52·0) NR NR 
Siegel (2018) 25 6* 6 51·0 1·6 3·1 
De Mattos-Arruda 
(2018) 26 
6 6 40·0 1·9 NR 
Schrijver (2018) 27 9 9 NR NR NR 
Diossy (2018) 28 17 17 55·90 (39·0-69·0) 2·3 (0·03-5·4) NR 
Tyran (2018) 29 14 14 51·0 (29-66) 4·3 (0-20·8) 1·3 (0·2-5·6) 
De Mattos-Arruda 
(2019) 30 
6 2 NR NR NR 





** MyChoice HRD performed on Illumina  
 
Table 2. Summary of sequencing methodologies and clinical material in the 13 included 
studies. The table summarises the different sequencing platforms used within the 13 studies, 
the clinical material and their receptor status by immunohistochemistry (IHC) and PAM50. 
NR: not recorded, PM: post-mortem, FFPE: formalin-fixed paraffin-embedded, SF: snap 















Da Silva (2010) 19 OncoCarta V1* Resection FFPE b NR table 
Lee (2015) 20 Ion-PGM Resection FFPE  b b table 
Saunus (2015) 21 Illumina HiSeq 
2000 
Resection SF b NR table 
Brastianos 
(2015) 18 
Illumina HiSeq Resection SF/FFPE b* NR Diagrams 
De Mattos-
Arruda (2015) 22 
Illumina HiSeq 
2000 
PM FFPE p NR xls 
Muller (2016) 23 Ion-PGM Resection SF/FFPE** 
1 case SF 
m NR table 
Richichi (2017) 24 Illumina HiSeq 
2000 
Resection FFPE p p table 
Siegel (2018) 25 Illumina HiSeq 
2500 
PM SF/FFPE p b xls 
De Mattos-
Arruda (2018) 26 
Illumina HiSeq 
2000 





Resection FFPE p NR xls 
Diossy (2018) 28 Illumina 
HiSeq** 
NR FFPE b NR Diagram 
Tyran (2018) 29 Illumina 
NextSeq500  
Resection SF b NR table 
De Mattos-
Arruda (2019) 30 
Illumina HiSeq 
2500 
PM/Resection SF p NR xls 
 30 
 
(B) BM N HER2+ HER2- HER2 NK 
/ ER+ / 
PgR NK 
TNBC 
ER+ ER- ER NK 
/ PgR 
NK 
ER+ ER- ER NK 
/ PgR 
NK 
PgR+ PgR- PgR 
NK 
PgR+ PgR- PgR 
NK 




Da Silva (2010) 19 12    3 5          4 
Lee (2015) 20 42   5   8    11     18 
Saunus (2015) 21 11   2   3    3     3 
Brastianos (2015)18 19       11      8   
Muller (2016) 23 4  2      1       1 
Diossy (2018) 28 19 1 2   5   3 2      6 
Tyran (2019) 29 14 2   1    3 2    1  5 
NK: Not Known 
Table 3. A summary of studies by the IHC status of the (A) primary tumour and (B) brain metastasis. The studies presenting 
immunohistochemistry status of (A) primary breast cancer and (B) brain metastasis are presented with the number of patients (N) included in each 
study.  
(A) BC N HER2+ HER2- HER2 NK 
/ ER+ / 
PgR NK 
TNBC 
ER+ ER- ER NK 
/ PgR 
NK 
ER+ ER- ER NK 
/ PgR 
NK  
PgR+ PgR- PgR 
NK 
PgR+ PgR- PgR 
NK 




Da Silva (2010) 19 12     4      3    5 
Lee (2015) 20 18      6    5     7 
Saunus (2015) 21 10   1   4    2  2  1  
Brastianos (2015)18 21       12      6  3 
De Mattos-Arruda 
(2015) 22 
4   1   1    1    1  
Muller (2016) 23 0                
Richichi (2017) 24 12 1    4   5 1      1 
Siegel (2018) 25 6        1       5 
De Mattos-Arruda 
(2018) 26 
6   3   3          
Schrijver (2018) 27 9      5         4 
Diossy (2018) 28 19 2 2   4   3 3      5 
Tyran (2019) 29 14 2    1   5 3      3 
De Mattos-Arruda 
(2019) 30 
6   2   1    2     1 
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P M P M P M P M P M P M 
Lee (2015) 20 15 5 2 0 2 4 4 5 6 1 1 0 0 
Richichi 
(2017) 24 
12 1 NR 5 NR 5 NR 1 NR 0 NR 0 NR 
Siegel 
(2018)25 
6 0 0 0 0 0 0 4 0 2 5 0 1 
 
Table 4. Reported PAM50 status of paired primary and brain metastasis samples.  
The 3 studies presenting the PAM50 status of primary breast cancer (P) and brain metastasis 
(M) are presented with the number of patients (N) included in each study. 
Potentially eligible 
studies identified by 
database search  (n=430)
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